Serono, Inc.


Mar 21, 07

NEW STORY
05:08 ET Merck Initiates Squeeze Out Procedure for Shares of Merck Serono S.A.

 
NEW STORY
02:15 ET Merck Serono Confirms Previously Announced 2006 Figures

 
Mar 01, 07

01:15 ET Merck KGaA Announces Serono Preliminary Figures for 2006

 
Jan 30, 07

01:15 ET Merck Serono Launches easypod(R), First Electronic Growth Hormone Injection Device

 
Jan 24, 07

01:15 ET Merck Serono Has Initiated the ONWARD Study to Evaluate Oral Cladribine as Add-on Treatment for Multiple Sclerosis

 
Jan 16, 07

09:30 ET Merck Serono Announces Positive Results From Phase III Diet Study of Phenoptin for Phenylketonuria

 
01:15 ET Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine

 
Jan 08, 07

01:15 ET Merck Serono is Launched

 
Jan 05, 07

16:46 ET Merck KGaA Acquires Majority Shareholding in Serono S.A.

 
Dec 20, 06

01:00 ET ZymoGenetics and Serono Begin Phase 2 Clinical Trial With Atacicept in Rheumatoid Arthritis

 
Dec 12, 06

01:00 ET Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis

 
Nov 13, 06

01:00 ET ZymoGenetics and Serono Report Detailed Positive Results From Atacicept Phase 1b Clinical Trial in Patients With Lupus

 
Oct 19, 06

01:00 ET Serono Delivers Strong Adjusted* Net Income of $183.5m in Third Quarter 2006

 
Oct 16, 06

01:00 ET Serono and Newron Announce Global Development and Commercialization Agreement for Safinamide

 
Oct 02, 06

01:00 ET Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer

 
Sep 28, 06

01:00 ET One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immunogenicity Profiles

 
Sep 25, 06

16:01 ET Serono: Publication of Interests (Art. 21 LBVM [Swiss Stock Market Law])

 
10:00 ET Study Shows Patient Preference for Gonal-f(R) RFF Pen to Treat Infertility

 
Sep 21, 06

08:41 ET Merck KgaA to Acquire Serono

 
01:00 ET Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status by FDA

 
Sep 18, 06

01:00 ET Serono and Syntonix to Pursue the Development of a Long-Acting, Inhaleable FSH Therapy to Treat Infertility

 
Sep 12, 06

07:00 ET BioMarin and Serono Announce Data on Phenoptin in PKU to be Presented at the 56th Annual Meeting of the American Society of Human Genetics

 
Aug 17, 06

16:05 ET Serono Announces Results From Pivotal Phase III Clinical Trial of Its Proprietary Recombinant Human Growth Hormone in the Treatment of HARS at the XVI International AIDS Conference

 
Jul 26, 06

16:01 ET Serono Delivers Second Quarter EPS of $12.92, Up 25.2% on Adjusted(1) Basis

 
Jul 10, 06

01:00 ET European Commission Approves Revision of Therapeutic Indication for Rebif(R)

 
Jun 26, 06

01:00 ET Zymogenetics and Serono Present Positive Results of TACI-Ig Phase 1b Trial in Rheumatoid Arthritis at Eular Meeting

 
May 09, 06

01:03 ET Serono Announces New Appointments to its Executive Management Board

 
Apr 25, 06

10:23 ET Serono Shareholders Approve Resolutions at Annual General Meeting

 
Apr 20, 06

01:02 ET Serono Delivers Strong First Quarter 2006 With Revenue Growth of 16.4% in Local Currencies

 
Apr 10, 06

01:02 ET Serono Announces Termination of Discussions Concerning a Sale of the Company

 
Apr 04, 06

01:02 ET Serono Submits New Formulation of Rebif(R) for Approval in the United States and in Europe

 
Mar 31, 06

00:02 ET Serono's Board of Directors to Propose an Increase in Authorized Share Capital to the Forthcoming Annual Shareholders' Meeting to Provide the Company With Financing Capacity

 
Mar 15, 06

16:04 ET BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU

 
Feb 06, 06

01:51 ET Serono's 2005 Adjusted(i) EPS Increased by 34.6%

 
01:02 ET Seronons 2005 Adjusted(i) EPS Increased by 34.6%

 
Jan 24, 06

01:02 ET Serono's Gonal-f(R) Approved in Japan for the Treatment of Male Hypogonadotropic Hypogonadism

 
Jan 09, 06

01:01 ET Serono Completes Second Phase III Trial of its Proprietary Recombinant Human Growth Hormone for HIV-Associated Adipose Redistribution Syndrome (HARS)

 
Dec 15, 05

13:19 ET Serono Announces Formal Conclusion of Serostim Settlement

 
Nov 09, 05

02:01 ET Immune Response to Influenza Vaccine is Maintained in MS Patients Treated With Rebif(R)

 
Nov 08, 05

07:09 ET Goldman Sachs Retained to Explore Strategic Alternatives

 
Nov 03, 05

08:01 ET Brooke Shields Lends Her Support to Encourage Women to Take Action Early if They Have Trouble Conceiving

 
Oct 25, 05

01:01 ET Serono and Rigel Sign Agreement to Develop and Commercialize Aurora Kinase Inhibitors

 
01:00 ET Serono's Third Quarter 2005 Adjusted EPS Increased by 37.6%

 
Oct 17, 05

11:40 ET Serono Announces Final Settlement of Serostim(R) Investigation

 
08:04 ET Serono Announces Significant Advances in Identifying Most Viable Embryos for Transfer During IVF Procedures

 
Oct 03, 05

17:30 ET Serono: Data And Safety Monitoring Board Recommends Discontinuation of Canvaxin(TM) Phase 3 Clinical Trial for Patients With Stage III Melanoma

 
Aug 18, 05

01:00 ET Serono and Genmab Announce Global Development and Commercialization Agreement for Humax-CD4

 
Aug 10, 05

08:31 ET Fertility LifeLines(TM) Offers Single Destination for Access to Infertility Information, Support and Savings

 
Jul 19, 05

16:04 ET Serono Delivers Strong Second Quarter Results

 
Jul 13, 05

02:54 ET Serono Welcomes Positive Ratings From Credit Agencies

 
May 17, 05

01:00 ET Serono and NovImmune to Collaborate in Development of Two Novel Treatments for Autoimmune Diseases

 
May 16, 05

00:30 ET BioMarin And Serono Form Strategic ALLIANCE for the Development and Commercialization of Phenoptin(TM) and Phenylase(TM)

 
Apr 26, 05

11:01 ET Serono Shareholders Approve Resolutions at Annual General Meeting

 
Apr 06, 05

01:00 ET Serono Announces Discontinuation of Onercept in Moderate-to-Severe Psoriasis and Canvaxin(TM) in Stage IV Melanoma

 
Mar 31, 05

00:00 ET Serono and Syntonix Sign Worldwide Agreement to Develop and Commercialize an Inhaleable Interferon-Beta Therapy for Multiple Sclerosis

 
Feb 01, 05

16:03 ET Serono Reports Strong Full Year 2004 Results

 
Jan 24, 05

01:00 ET Serono Announces Completion of Patient Enrollment in Phase III Trial of Serostim(R) (Somatropin [rDNA Origin] for Injection) in HIV-Associated Adipose Redistribution Syndrome (HARS)

 
Jan 11, 05

01:00 ET Serono and IVAX to Initiate Phase III Clinical Trial of Mylinax(R) in Multiple Sclerosis

 
Jan 10, 05

01:00 ET Serono Announces the Availability of Saizen(r) for Adult Growth Hormone Deficiency (AGHD) in the United States

 
Dec 20, 04

08:01 ET Serono Announces FDA Approval of Rebif(R) Titration Pack

 
Dec 07, 04

01:00 ET Serono and Micromet to Collaborate in Development and Commercialization of Novel Anti-Cancer Drug

 
Nov 15, 04

01:00 ET Serono and Nautilus Biotech Sign Worldwide Agreement to Develop and Commercialize a Next-Generation Growth Hormone

 
Nov 10, 04

01:00 ET Serono Announces Appointment of New Chief Financial Officer

 
Oct 27, 04

01:00 ET Serono and Paratek Pharmaceuticals in Partnership to Develop a Novel Oral Treatment for Multiple Sclerosis

 
Oct 19, 04

07:30 ET Clinical Study Shows Need for Fewer Injections to Prevent Premature Ovulation During the Treatment of Infertility

 
Oct 15, 04

01:00 ET FDA Approves Serono's Luveris(R) for Concomitant Use With Gonal-f(R)

 
Oct 08, 04

01:00 ET Four Year Data Shows 54% Reduction in Relapse Rate and 76% of MS Patients Remain Free of Disease Progression With Rebif(R)

 
Sep 08, 04

01:00 ET ZymoGenetics and Serono Establish Broad Strategic Research, Development and Commercialization Alliance

 
Sep 03, 04

01:00 ET Serono Concludes New License Agreement

 
Jul 21, 04

16:38 ET Strong Second Quarter With Robust EPS Growth of 28.5%

 
16:22 ET Strong Second Quarter With Robust EPS Growth of 28.5%

 
Jun 01, 04

01:00 ET Serono Initiates Phase III Trial of Serostim(R) in HIV-Associated Adipose Redistribution Syndrome

 
May 27, 04

01:00 ET Serono Receives FDA Approval for Gonal-F(R) Pen to Treat Infertility

 
May 25, 04

10:32 ET Serono Shareholders Approve Resolutions at Annual General Meeting

 
01:00 ET Serono Announces New Share Buy-Back Program for up to CHF 750 Million

 
May 04, 04

01:30 ET Serono Launches Zorbtive(TM), First Drug Product for Treatment of Short Bowel Syndrome

 
01:00 ET 4SC AG and Serono Sign Worldwide Agreement to Develop and Commercialize Orally Active Compounds for the Treatment of Autoimmune Disorders

 
Apr 29, 04

01:00 ET Serono Announces Management Change

 
Apr 28, 04

01:00 ET MS Patients Taking High Dose High Frequency Rebif(R) Sustained Reduction in Accumulation of MRI Brain Lesions Over Long Term

 
Apr 23, 04

09:00 ET Serono Offers 'Lifeline' To People With Fertility Health Concerns

 
Mar 31, 04

00:01 ET Serono's Serostim(R) Improves Lean Body Mass and Physical Performance in Patients With HIV-Associated Wasting

 
Mar 29, 04

09:04 ET Serono Receives FDA Approval for New Presentations of Gonal-f(R) to Treat Infertility

 
Mar 23, 04

01:00 ET Serono and IVAX Announce Positive Outcome of Pharmacokinetic Trials With Oral Cladribine

 
Mar 18, 04

09:05 ET Serono Launches www.Seronofertility.com

 
Mar 16, 04

01:00 ET Raptiva(R) (Efalizumab) Receives Approval for Moderate-to-Severe Plaque Psoriasis in Switzerland

 
Mar 01, 04

01:00 ET Treatment With Serostim Decreased Visceral Adipose Tissue in Study of Patients With HIV-Associated Adipose Redistribution Syndrome (HARS)

 
Feb 25, 04

01:00 ET European Commission Approves GONAL-f(R) Filled-by-Mass Prefilled Pen

 
Feb 23, 04

18:01 ET Serono and Swedish Biotech Company InDex Pharmaceuticals Sign Worldwide Agreement to Develop and Commercialize Novel Ulcerative Colitis Treatment

 
Feb 12, 04

01:01 ET Low Dose Maintenance Therapy With Recombinant Human Growth Hormone May Sustain Previous Serostim(R) Treatment In HIV Positive Patients With HARS

 
Feb 02, 04

17:00 ET Record Year for Serono With Over $2 Billion in Revenues

 
Jan 21, 04

08:58 ET Publication of the First Dictionary of Multiple Sclerosis Provides a Valuable Reference Tool for MS Healthcare Professionals and Patients

 
Dec 15, 03

07:00 ET Serono, Inc. Launches New Web Site For People with Worsening Multiple Sclerosis and their Physicians

 
Dec 02, 03

01:00 ET FDA Approves Serono's Zorbtive(TM) for Use in Patients With Short Bowel Syndrome

 
Nov 10, 03

08:06 ET New Survey Highlights Opportunity for People with Multiple Sclerosis to Better Manage and Track Disease Progression

 
Oct 30, 03

01:00 ET European Commission Approves Serono's Ovitrelle(R) Solution For Injection In a Pre-Filled Syringe For Treatment of Infertility

 
Oct 23, 03

01:01 ET Serono Reports Strong Third Quarter Results

 
Oct 08, 03

07:02 ET FDA Approves Serono's Ovidrel(R) Prefilled Syringe for Treatment of Infertility

 
Sep 30, 03

18:53 ET FDA Advisory Committee Issues Favorable Recommendation for Efficacy of Luveris(R) in Follicular Development

 
Sep 19, 03

01:31 ET New Positive Long-Term Results For Rebif(R) Multiple Sclerosis Treatment Presented at ECTRIMS

 
Aug 29, 03

15:03 ET Serono's Serostim(R) Receives Full Approval From FDA For Treatment of Aids Wasting

 
Jul 29, 03

13:00 ET The Serono Foundation Awards Three Scientists With Fellowships for Research in Cancer Biology

 
Jun 30, 03

09:30 ET Serono Announces Promising Results for Emfilermin, a New Drug for Improving Implantation of Embryos

 
Jun 25, 03

20:02 ET Serono Announces Results Of FDA Advisory Committee On Serostim(R) For Use In Patients With Short Bowel Syndrome

 
Jun 22, 03

08:30 ET Serono Announces Positive Results For Onercept in Psoriasis and Psoriatic Arthritis In Phase II Trials

 
Jun 18, 03

08:06 ET MS Patients Converting From Avonex(R) to Rebif(R) Showed Significant Reduction in Frequency of Relapses and MRI Lesion Activity

 
May 30, 03

08:00 ET Final 63-week Evidence Study Data Continue to Show Rebif(R) Significantly More Effective Than Avonex(R) in Reducing Frequency of Relapses and MRI Activity in Relapsing Forms of MS

 
May 22, 03

08:01 ET REBIF(R) Labeling Changes reflect Efficacy and Convenience of The FASTEST GROWING MS Treatment in the U.S.

 
Apr 24, 03

01:00 ET Serono Announces Good First Quarter Results with Strong Revenue Growth

 
Apr 04, 03

08:01 ET Rebif(R) Teams up with The National Multiple Sclerosis Society to Sponsor MS Walks in 225 Cities Nationwide in 2003

 
Mar 25, 03

16:44 ET Serono Announces New Senior Management Appointments

 
Feb 06, 03

01:00 ET Serono and Genentech Expand Raptiva Agreement to Additional Emerging Markets in Asia

 
Feb 03, 03

01:00 ET Serono 2002 Revenues Break Through the $1.5 Billion Mark; Product Sales Up 13.9% to $1.42 Billion

 
Dec 18, 02

17:00 ET Serono and Amgen Close Agreement For U.S. Commercialization of Novantrone

 
Dec 02, 02

06:33 ET Serono Ceases Purchase of Genset Shares on Nouveau Marche at euro 9.75

 
01:00 ET Serono Ceases Purchase of Genset Shares on Nouveau Marche at euro 9.75

 
01:00 ET Serono to Hold R&D Day for Investors and Analysts Today

 
Nov 25, 02

16:11 ET Multiple Sclerosis Patients on Rebif(R) More Likely to Remain Relapse Free Than Patients on Avonex(R) at 48 Weeks

 
Nov 08, 02

05:00 ET Results of Serono Tender Offer

 
Oct 31, 02

12:31 ET Serono Tender Offers for Genset Expire

 
Oct 23, 02

01:00 ET Serono Reports Strong Growth with Third Quarter Sales Up 18%

 
Oct 14, 02

08:33 ET Overcoming the Wall of Infertility

 
Oct 09, 02

01:00 ET Serono and Cellular Genomics Announce Joint Kinase Discovery Program

 
Oct 02, 02

09:31 ET Serono Implements New Serostim(R) Secured Distribution Program

 
Sep 30, 02

09:40 ET Serono Announces Positive Results of Serostim(R) Clinical Trial for Treatment of HIV-Related Metabolic Complication

 
Sep 23, 02

02:49 ET Serono's Cash Offers for Genset Are Successful

 
Jul 24, 02

01:00 ET Serono Reports Second Quarter Underlying Net Income Up 16.1%

 
Jul 23, 02

01:00 ET Serono and AstraZeneca Sign Agreement for Development of New Therapy in the Area of Female Infertility

 
Jul 11, 02

01:00 ET Serono and Pfizer to Co-Promote Multiple Sclerosis Treatment Rebif(R) in the United States

 
Jul 10, 02

08:31 ET Serono to Make CostDoctor Software Available to Fertility Specialists Through Exclusive Distribution Agreement

 
Jun 26, 02

01:00 ET Recommended Cash Offer for Genset by Serono - Firm Value of EUR 107.4 Million Based on a Price per Share of EUR 9.75 -

 
Jun 06, 02

01:00 ET Cool.click(TM) Needle-Free Device for Growth Hormone Receives Authorization for Marketing in EU

 
Jun 04, 02

16:10 ET Serono Announces Settlement with Columbia Laboratories Related to Crinone(R)

 
May 28, 02

01:00 ET Serono Announces Outcome of Three Clinical Studies

 
May 16, 02

16:10 ET Serono Issues Notification of Counterfeit Serostim(R)

 
Apr 19, 02

16:01 ET Serono Sponsors The MS Walk(R) 2002 in Massachusetts and New Hampshire

 
Apr 16, 02

18:29 ET EVIDENCE Study Data Confirms That Patients Treated With Rebif(R) Are More Likely to Remain Free of Relapses During 48 Weeks Than Patients on Avonex(R)

 
Mar 12, 02

01:00 ET Serono Reintroduces Crinone(R) To US Market

 
Mar 11, 02

01:00 ET Serono's Rebif(R) Launched Today in US

 
Mar 08, 02

04:00 ET Serono's rebif(R) Receives FDA Approval

 
Feb 13, 02

01:00 ET Serono Announces 2001 Underlying Sales Growth of 15%

 
Feb 12, 02

07:02 ET Serono Launches SeroJet(TM) Needle-Free Device to Deliver Serostim(R) Human Growth Hormone

 
Dec 20, 01

01:00 ET Serono Subscribes to Celera's Genomic Databases

 
Nov 28, 01

16:15 ET Serono Believes Crinone(R) Not Yet Ready For Re-Launch

 
Oct 30, 01

01:00 ET Serono Reports Rebif(R) Growth of 47% and Announces Early Investment For Rebif(R) in the US

 
Oct 08, 01

01:01 ET Serono Confirms Submission of Rebif(R) BLA Amendment to FDA

 
Aug 31, 01

12:40 ET Infertility Legislation Signed into Law, Reports RESOLVE of New Jersey

 
Aug 19, 01

13:43 ET Serono Now Free to Communicate Full Results of the EVIDENCE Study To Healthcare Professionals

 
Jul 24, 01

01:01 ET Serono Announces Record Quarter Results

 
Jul 12, 01

01:01 ET Serono Holds First Investor and Analyst R&D Day

 
Jun 28, 01

17:00 ET Family Building Act Passes the New Jersey Assembly

 
06:16 ET Results of Four-Year Study of Rebif(R) Published in Neurology

 
Jun 24, 01

07:00 ET Family To Share Their Story of Successful Pediatric Growth Hormone Treatment With Needle-Free Delivery System at BIO 2001

 
Jun 22, 01

08:01 ET Results of Evidence Study of Rebif(R) Versus Avonex(R) Presented at the World Congress of Neurology in London

 
Jun 20, 01

11:01 ET EVIDENCE Study Data to be Presented at the XVII World Congress of Neurology, London on Friday, 22 June 2001

 
Jun 14, 01

08:31 ET Infertile Couples Support Bill to Mandate Insurance Coverage for Infertility Treatment

 
Jun 13, 01

14:01 ET Major Breakthrough to Improve Detectability of Mad Cow and Other Prion Diseases

 
Jun 12, 01

01:01 ET Serono's Extensive MS Research Program to Be Featured in Scientific Journals and Presentations This Month

 
May 17, 01

16:46 ET Serono Issues Information on New Counterfeit Serostim(R) LOT

 
May 16, 01

01:00 ET Serono and Alkermes to Proceed with Development of Long-Acting Formulation of Recombinant Human Follicle Stimulating Hormone (r-hFSH)

 
May 15, 01

11:01 ET Serono Shareholders Approve Resolutions at Annual General Meeting

 
May 08, 01

01:24 ET Serono Announces Highly Significant Positive Outcome Of Rebif(R) vs Avonex(R) Study in Multiple Sclerosis

 
May 02, 01

01:00 ET Serono Reports Strong Growth in Q1 2001

 
Mar 22, 01

01:00 ET Thomas A. Lang Appointed President of Serono, Inc.

 
Jan 22, 01

16:15 ET Serono Statement Regarding Counterfeit Serostim(R)

 
Oct 23, 00

07:59 ET Serono Recognizes Award Winners From Fertility Nursing Centers of Excellence

 
Sep 21, 00

08:59 ET Serono Introduces BABIES(TM) Infertility Benefit Assessment Software During National Infertility Awareness Week (Sept. 17-23)

 
Sep 18, 00

08:59 ET Serono Introduces Comprehensive Online Fertility Resource

 
Jun 26, 00

01:00 ET Serono Receives FDA Market Clearance For First Needle-Free Device To Deliver Saizen(R) Human Growth Hormone For US Pediatric Market

 
Jun 05, 00

01:01 ET Serono Receives New US Marketing Approvals For Gonal-F(R) for Treatment of Infertility in Both Women and Men

 
May 22, 00

08:29 ET Serono Announces Latest Information On Use of Vaginal Progesterone Gel For Patients Experiencing Infertility

 
May 02, 00

10:05 ET Multiple Sclerosis: New Four-Year Data From Ares-Serono Study Shows Benefits of Early Treatment With High Dose Interferon Beta-1a

 
Mar 27, 00

13:10 ET Biotechnology Brings Hope To Infertile Couples

 
Mar 23, 00

11:46 ET Long Term Data From Multiple Sclerosis Study With Rebif(R) Confirm Dose- Related Effect and Reinforce Need to Treat MS Patients Early and With Highest Tolerable Dose

 
Feb 09, 00

11:28 ET New Web Site Resource Available to Help Parents Understand Growth Disorders in Children

 
Jan 28, 00

08:59 ET Ares-Serono and AMRAD Sign an Agreement for Development of 'LIF' In Reproductive Health

 
Jan 18, 00

10:55 ET Ares-Serono Sales Break US$1 Billion Mark

 
Jan 14, 00

07:01 ET New Potential Approach for the Treatment of Brain Diseases, Leading to Possible Understanding of Creutzfeldt-Jakob Disease and Alzheimer's Disease

 
Jan 11, 00

08:51 ET Ares-Serono and Alkermes Sign Agreement for the Development Of a Prolease(R) Formulation of a Therapeutic Protein

 
Jan 06, 00

17:51 ET Serono Laboratories, Inc. and Bioject Medical Technologies, Inc. Announce Agreement for Needle-Free Delivery of Saizen(R) Human Growth Hormone

 
Nov 19, 99

10:34 ET Serono Laboratories Concurs With Medical Community On New Initiatives To Minimize Multiple Births

 
Nov 02, 99

09:08 ET Ares-Serono Posts Excellent Nine Months and Record Third Quarter Results

 
Oct 05, 99

08:29 ET Ares-Serono Initiates a Head-To-Head Trial Comparing Rebif(R) And Avonex(R) in Relapsing Remitting Multiple Sclerosis

 
Sep 27, 99

08:33 ET Interim Results of Treatment Protocol Positive on Crinone(R)

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2007 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.